Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 3/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474364 | 0.91 | TRPV1 (0.37) | KDM4ETSHRHSD17B10TRPV1 | |
| SCHEMBL1473416 | 0.90 | PDE2A (0.37) | TRPV1ADRB3ACACBGPR139PDE2A | |
| SCHEMBL13685642 | 0.90 | PDE2A (0.37) | TRPV1ADRB3ACACBGPR139PDE2A | |
| SCHEMBL13500684 | 0.90 | PDE2A (0.37) | TRPV1ADRB3ACACBGPR139PDE2A | |
| SCHEMBL1473728 | 0.90 | TRPV1 (0.37) | TRPV1ADRB3ACACBGPR139PDE2A | |
| SCHEMBL1473509 | 0.89 | KDM4E (0.35) | KDM4ETSHRHSD17B10TRPV1PDE2A | |
| SCHEMBL1473099 | 0.86 | TRPV1 (0.37) | TRPV1ADRB3ACACBGPR139PDE2A | |
| SCHEMBL13685075 | 0.86 | TRPV1 (0.35) | TRPV1ADRB3GPR139PDE2A | |
| SCHEMBL1476317 | 0.81 | TRPV1 (0.39) | TRPV1ADRB3ACACBGPR139CNR2 | |
| SCHEMBL1476204 | 0.80 | CNR2 (0.37) | TRPV1ACACBGPR139PDE2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915448-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | KDM4E 4595/4885TSHR 185/4885HSD17B10 2121/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | KDM4E 4651/4885TSHR 165/4885HSD17B10 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.